Special Drug Use Investigation for ADOAIR DISKUS COPD (Salmeterol and Fluticasone)
To investigate possible problems or questions in safety and effectiveness of salmeterol and fluticasone in patients with chronic obstructive pulmonary disease (bronchitis chronic / emphysema). In this special drug use investigation, onset of pneumonia shall be handled as the priority investigation item.
|Study Design:||Time Perspective: Prospective|
|Official Title:||Special Drug Use Investigation for ADOAIR DISKUS COPD (Salmeterol and Fluticasone)|
- The incidence of adverse events in Japanese patients treated with salmeterol and fluticasone based on prescribing information under the conditions of general clinical practice. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
|Study Start Date:||August 2009|
|Study Completion Date:||January 2013|
|Primary Completion Date:||April 2012 (Final data collection date for primary outcome measure)|
Patients prescribed salmeterol and fluticasone
Patients with chronic obstructive pulmonary disease prescribed salmeterol and fluticasone during study period
Drug: Salmeterol and Fluticasone
Administered according to the prescribing information in the locally approved label by the authorities.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01332409
|GSK Investigational Site|
|Chiba, Japan, 296-8602|
|Study Director:||GSK Clinical Trials||GlaxoSmithKline|